JBNF-BioMed presents: 

Wednesday, July 29th, 2015

with as participating Biomed Startups:

Precise Bio, presented by Dr Aryeh Batt, CEO and founder

•  Sleep ASAP, presented by Hemda Idel, CEO and co-founder

                            and Nadav Landkin, COO and co-founder 

• LBSight, presented by Dr Barak Katz, CEO and founder

The Biomed Startups will pitch to a panel composed by the following:

• Yaron Magal, CTO, Terralab/Terra Venture Capital

Morris Laster, Venture Partner. Our Crowd

and finalizing with others from the investment community.

JBNF-Biomed is launching a series of startup pitch evenings, to be held every three months. The first one will be held on biomed but we intend also to hold such events for pharma. The purpose of these events is to give a platform for promising life science start-ups to present themselves to a forum of investors. In addition, it will help other bio-entrepreneurs to learn to better pitch their start-ups and to acquaint themselves with investors.

Sponsored by the JCT – Lev Academic Center  and the Jerusalem Business Networking Forum – Biomed Division

RVSP to reserve your place. There is a 20 NIS entrance fee to the event. 

Bring business cards for the great networking!

For questions, contact us at info@jbnf.org

Business Executive Summaires for the 3 Biomed Startups

Sleep ASAP (Art Science Awareness Platform) -Sleep-management education through technology

“Insufficient Sleep Is a Public Health Epidemic. People experiencing sleep insufficiency are also more likely to suffer from chronic diseases such as hypertension, diabetes, depression, and obesity as well as from cancer”

 ______________________________________________Dr. James Maas

Abstract: Sleep deprivation affects 45% of the world, and this number is growing, with 50-70 million sufferers in the US alone. In the US the direct annual costs is estimated at $13.9 billion, with an additional indirect annual cost (lost work productivity, insomnia-related health issues and work accidents, etc.) of $77-92 billion. (* CDC – Center for Diseases Control and prevention) Watch a quick movie


Personalized Treatment

To date available treatments are generic, costly and often pharmaceutical. Sleep ASAP provides personalized sleep solutions based on formal studies, data collection and advanced learning algorithms that matches the sleep struggler to an optimal personalized treatment modality.

Sleep Mapping data

One outcome of Sleep ASAP platform will be a large scale database dedicated to sleep-related data. This data will then be mashable with other databases that focus on other physiological, social and geographic parameters. This “sleep mapping” of the world will be the first of its kind and will transform the field of sleep research.SLEEP ASAP is the only global platform of its kind covering multiple distinct geographically distant communities on one hand, that still share a great deal in terms of their sleep disorders across various statistical domains.The SLEEP ASAP platform is constantly updated resource of curated professional and lay literature on all aspects of sleep disorders and functions as an online library and resource to all comers.The universal social platform addresses both the sleep struggler and the service provider (therapist, physician, HMO).

Key Features

One of the key features will be as a review site for many IoT devices for sleep management, monitoring and improvement. This type of information will be generated by sleep specialists and will be unique in its composition.

The Future of the Sleep Medicine

Ultimately, this platform will select and match the optimum personalized treatment option for each user. This one feature will save countless people a tremendous amount of time and frustration, by helping sleep strugglers to find the most efficient path to a better night’s sleep.

Revenue: Two Sided MarketMarketplace of therapies: 25% Revenue Sharing + Membership fee for both sides


Hospital Acquired Infections (HAI) are responsible for 75,000 American casualties a year [1]. HAI implies prolonged hospital stays and costs the healthcare system more than $40B a year [2]. Organisms causing HAIs are invisible to the naked eye and are hard to locate, yet can be transmitted to patients on stuff hands and via contaminated environments. Researchers have reported that within 3 hours a virus could be detected on 50% of workers and visitors in the facility and commonly touched objects, due to contamination of just a single table or doorknob [3]. Proper usage of disinfecting wipes along with hand hygiene have reduced virus spread by 80% to 99% [3], while proper implementation of best practice hand hygiene standards have reduced HAI transmission rates by 28% [4].Today, detecting contaminated surfaces or monitoring compliance with best practice hand hygiene standards are primarily monitored by random direct staff observation. Available automatic solutions only monitor healthcare worker compliance with hand hygiene standards upon entering and exiting patient zones. However, these solutions fall short of automatically and reliably detecting hand contact, the most critical phase of germ transmission. Hence, healthcare providers are strongly dependent on their staff and visitors awareness and goodwill to follow proper surface hygiene and hand hygiene procedures.This is where LBSIGHT comes into play. LBSIGHT patents pending solutions monitor hand contact in patient surroundings as well as hand contact with the most vulnerable areas of the patient’s body, and then provide the interactive means to the achievement of safer hospitals. LBSIGHT monitors the patient zone, pinpointing the locations of contaminate surfaces through hand contact and provides exclusive solutions that interactively empower staff, patients, and family members to easily and instantly sanitize infected areas. Hence, LBSIGHT can improve hygiene awareness, increase compliance, can reduce HAI and the familiar helplessness and anxiety about touching surfaces within patient zones without knowing whether those areas are contaminated.In addition LBSIGHT can automatically monitor the best practice hands hygiene standard, particularly before and after an aseptic procedure when touching wounds, bandages, catheters and other vulnerable areas of the body. Early alerts of possible HAI events, Safety PPE removal, and assisting workers reduce the spread of cold and flu germs throughout their offices are additional means of prevention that will be provided by LBSIGHT.

The Opportunity

HAIs account for more than 20% of total ICU costs, and increase the average US hospital charges per infection from $35,168 to $191,872 [5]. At the same time, hospitals are not reimbursed for the established HAI costs [6]. In addition, the healthcare reform Value Based Purchasing (VBP), and the Hospital Consumer Assessment of Healthcare Providers and Systems scores (HCAHPS) provide US medical centers significant economic incentives for better services and for more accountable care. The VBP distributes an estimated $850M to hospitals based on their overall performance, and hospitals will face reductions in their Medicare payments if they do not use IT to deliver better and safer care. These facts are the main reason that hygiene becomes the fastest growing segment in the Infection Control market [7]. Flu epidemic and Antimicrobial Resistance (AMR) have significant impact as well.

Business Model

LBSIGHT will license its SafeCare platform to healthcare providers on a yearly basis and in addition will charge per usage operational fee. LBSIGHT will distribute directly to selected customers as well as collaborate with a leading industry partner that will deploy SafeCare at healthcare provider sites.Company 


Barak Katz, PhD, Israel, and Ofer Cohen, BSc, Israel, founded LBSIGHT in 2014. Prof. Abraham Borer, MD (Infection Control Director, Clalit Health Services), Prof. Joseph Rosen and Mr. Menasha Rothschild joined LBSIGHT as advisory members. LBSIGHT has developed its prototype platform which has garnered extremely positive feedback from the world’s top opinion leaders, leading US medical centers, and US industry leaders. Top CDC (US‐Atlanta) HAI leaders have expressed their interest in integrating SafeCare into three different CDC research efforts.

For further information: Barak Katz barak@lbsight.com, +972‐528‐744474

[1] <a>www.cdc.gov/HAI/surveillance/</a>

<a>[2]</a> <a>www.cdc.gov/hai/pdfs/hai/scott_costpaper.pdf</a>

<a>[3]</a> <a>www.medicaldaily.com/virus‐spreads‐rapidly‐within‐2‐4‐hours‐how‐disinfecting‐wipes‐quaternary‐ammonium‐301740</a>

<a>[4]</a> <a>www.hopkinsmedicine.org/heic/docs/Hand_hygiene_fact_sheet.pdf</a>

<a>[5]</a> Hospital Epidemiology and Infection Control in Acute ‐ Care Settings

[6] Hospital‐acquired Infections Report ‐ Pennsylvania Healthcare

[7] Infection Control Market, Sterilization and Disinfection – Global Forecast To 2017

Yaron Magal, CTO at Terralab/Terra Venture Capital

He was involved in the sale of Lightech to “GELighting” and proceeded to setup and manage “GE Lighting”, 2nd GE corporate design center in Israel and the first in Israel for “GE Lighting” subsidiary. He was vp R&D at Mango DSP and held for 22 Year of C-Level positions in the IDF prestige technological core and Hi-Tech industry. He is a graduated with a BSc in Electronics & E-Optics from JCT. 

Morris Laster, M.D, Venture Partner at OurCrowd

Dr. Morris Laster is a healthcare executive/entrepreneur with over 25 years of experience in the biopharmaceutical industry. Currently, Morris is the Venture Partner responsible for Medtech investments at OurCrowd (www.ourcrowd.com) a world leading crowd funding platform that has invested over $140M for  70 companies over the last two years, 12 of them in the Medtech space. He has invented a novel device to access the circulatory system through the bone marrow, a technology being developed as Xerem Medical in the Rad-Biomed Incubator in Tel Aviv beginning in 2015.  From 2010-2013 he was a founder and director at Kitov Pharmaceuticals (TASE:KTOV) currently in Phase 3 clinical trials for a NSAID with reduced cardiovascular risk.  From 2003-2010 he was the founding CEO of BioLineRx (NASDAQ/TASE:BLRX). From 1997-2002 he was the Chairman and CEO of Keryx Biopharmaceuticals (NASDAQ:KERX) where he led the first simultaneous NASDAQ/AIM listing in 2000 and secured a breakthrough Subpart H surrogate endpoint trial for its Phase 3 Diabetic Nephropathy drug. He began his entrepreneurial career as a VP of medical venture capital at Paramount Capital in NYC while a fourth year medical student. From 1990-1993, while in that capacity he founded three companies that went public. XTL Therapeutics (NASDAQ:XTLB) which developed hepatitis B and C antibodies in programs that were licensed to Cubist, Progenitor (NASDAQ:PGEN) which was developing yolk sac derived stem cells and Neose Technologies (NASDAQ: NTEC) which specialized in the enzymatic synthesis of oligosaccharides. He received his MD from Downstate Medical Center, Brooklyn, NY in 1990 and a BS in Biology from SUNY Albany.